Anales de la RANM

27 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 LA DETECCIÓN DE LA ENFERMEDAD MÍNIMA RESIDUAL Díaz-Rubio E An RANM. 2026;143(01): 16 - 27 38. Bando H, Watanabe J, Kotaka M et al. Phase III randomized study of trifluridine/tipira- cil (FTD/TPI) versus placebo in patients with molecular residual disease following cura- tive resection of colorectal cancer (ALTAIR; NCT04457297). Presented at: ESMO Gastroin- testinal Cancers Congress 2025; 2–5 Jul 2025; Barcelona, Spain. Ann Oncol 2025;36 (supp S1) Abstract 30. 39. Kasi PM, Aushev VN, Langer N, et al. Circu- lating tumor DNA for informing adjuvant che- motherapy in stage II/III colorectal cancer: interim analysis of the BESPOKE CRC study. J Clin Oncol. 2024;42(Suppl 3):9. 40. Tie J, Cohen JD, Wang Y, et al. ctDNA-infor- med adjuvant chemotherapy in locally advan- ced rectal cancer: DYNAMIC-Rectal. J Clin Oncol. 2024;42(Suppl 3):12. 41. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA as- say in colorectal cancer. Clin Cancer Res. 2021;27(20):5586–5594. 42. Nakamura Y, Tsukada Y, Matsuhashi N, et al. Colorectal cancer recurrence predic- tion using a tissue-free epigenomic mini- mal residual disease assay. Clin Cancer Res. 2024;30(19):4377–4387. 43. Lonardi S, Pietrantonio F, Tarazona N, et al. The PEGASUS trial: post-surgical liquid biopsy–guided treatment of stage III and high-risk stage II colon cancer. Ann Oncol. 2023;34(Suppl):S1268–S1269. 44. Morris VK, Yothers G, Kopetz S, et al. Cir- culating tumor DNA as a predictive biomar- ker in adjuvant chemotherapy for stage II colon cancer: COBRA trial. J Clin Oncol. 2024;42(Suppl):5. 45. Negro S, Pulvirenti A, Trento C, et al. Circula- ting tumor DNA as a real-time biomarker for minimal residual disease and recurrence pre- diction in stage II colorectal cancer. Int J Mol Sci. 2025;26(6):2486. Si desea citar nuestro artículo: Díaz-Rubio E. La gran oportunidad: La detección de la enfermedad mínima residual (EMR) en el cáncer colorrectal localizado me- diante ADN tumoral circulante (ADNtc). An RANM. 2026;143(01): 16– 27. DOI: 10.32440/ar.2026.143.01. rev01